Recommendation of the President – Jardiance (empagliflozin)
On 23 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 152/2024 on the inclusion in reimbursement of the medicinal product Jardiance (empagliflozin) for the indication: chronic kidney disease in adult patients with: eGFR in the range of ≥ 20 ml/min/1.73 m2 to < 45 ml/min/1.73 m2, taking ACEi/ARB-based therapy for at least 4 weeks or with a contraindication to such therapy or eGFR in the range of ≥ 45 ml/min/1.73 m2 to < 90 ml/min/1.73 m2 and albuminuria or proteinuria, taking ACEi/ARB-based therapy for at least 4 weeks or with a contraindication to such therapy